Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Tóm tắt
Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.
Từ khóa
Tài liệu tham khảo
Rossi, 2009, The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors., Br J Haematol, 146, 64, 10.1111/j.1365-2141.2009.07711.x
Moreira, 2013, Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls., Leukemia, 27, 136, 10.1038/leu.2012.187
D’Arena, 2012, A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia., Am J Hematol, 87, 628, 10.1002/ajh.23170
D’Arena, 2011, Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease., Leuk Res, 35, 363, 10.1016/j.leukres.2010.08.010
Palmer, 2008, Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia., Br J Haematol, 141, 607, 10.1111/j.1365-2141.2008.07070.x
Rozman, 1988, Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance., Cancer, 61, 279, 10.1002/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia., N Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia., Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia., N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia., N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222
Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia., Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415
Evans, Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells [published online ahead of print June 18, 2015]., Br J Haematol
Sotillo, 2015, Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy., Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020
Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias., Blood, 118, 4817, 10.1182/blood-2011-04-348540
Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells., Blood, 119, 2709, 10.1182/blood-2011-10-384388
Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia., Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226
Dubovsky, 2013, Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes., Blood, 122, 2539, 10.1182/blood-2013-06-507947
Sagiv-Barfi, 2015, Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK., Proc Natl Acad Sci USA, 112, E966, 10.1073/pnas.1500712112
Hertlein, 2013, Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease., PLoS One, 8, e76607, 10.1371/journal.pone.0076607
Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo., Mol Ther, 17, 1453, 10.1038/mt.2009.83
Parish, 2009, Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation., Curr Protoc Immunol, 10.1002/0471142735.im0409s84
Porter, 2006, A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation., Blood, 107, 1325, 10.1182/blood-2005-08-3373
Riches, 2013, T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production., Blood, 121, 1612, 10.1182/blood-2012-09-457531
Bennett, 2003, Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses., J Immunol, 170, 711, 10.4049/jimmunol.170.2.711
Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation., J Immunol, 173, 945, 10.4049/jimmunol.173.2.945
Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms., Mol Cell Biol, 25, 9543, 10.1128/MCB.25.21.9543-9553.2005
Okazaki, 2001, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine., Proc Natl Acad Sci USA, 98, 13866, 10.1073/pnas.231486598
Patsoukis, 2012, Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation., Sci Signal, 5, ra46, 10.1126/scisignal.2002796
Patsoukis, 2012, PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A., Cell Cycle, 11, 4305, 10.4161/cc.22135
McClanahan, 2015, PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia., Blood, 126, 203, 10.1182/blood-2015-01-622936
Wong, 2012, Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice., Cancer Res, 72, 4931, 10.1158/0008-5472.CAN-12-1390
Coles, 2011, CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia., Leukemia, 25, 792, 10.1038/leu.2011.1
Kretz-Rommel, 2007, CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy., J Immunol, 178, 5595, 10.4049/jimmunol.178.9.5595
Wong, 2010, The role of CD200 in immunity to B cell lymphoma., J Leukoc Biol, 88, 361, 10.1189/jlb.1009686
Kohrt, 2014, Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity., Blood, 123, 1957, 10.1182/blood-2014-01-547869
Woyach, 2014, Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib., N Engl J Med, 370, 2286, 10.1056/NEJMoa1400029
Cheung, 2010, Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis., Cancer Res, 70, 9166, 10.1158/0008-5472.CAN-10-2460
Steidl, 2011, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers., Nature, 471, 377, 10.1038/nature09754
Peretz, 2012, CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction., PLoS Pathog, 8, e1002840, 10.1371/journal.ppat.1002840
Alapat, 2012, Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma., Am J Clin Pathol, 137, 93, 10.1309/AJCP59UORCYZEVQO
Dorfman, 2010, CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms., Am J Clin Pathol, 134, 726, 10.1309/AJCP38XRRUGSQOVC
Gorczynski, 1999, Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells., J Immunol, 162, 774, 10.4049/jimmunol.162.2.774
Shiratori, 2005, Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200., J Immunol, 175, 4441, 10.4049/jimmunol.175.7.4441
Gorczynski, 2001, Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages., Eur J Immunol, 31, 2331, 10.1002/1521-4141(200108)31:8<2331::AID-IMMU2331>3.0.CO;2-#
Jenmalm, 2006, Regulation of myeloid cell function through the CD200 receptor., J Immunol, 176, 191, 10.4049/jimmunol.176.1.191
Pallasch, 2009, Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade., Leuk Res, 33, 460, 10.1016/j.leukres.2008.08.021
Ramsay, 2012, Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer., Blood, 120, 1412, 10.1182/blood-2012-02-411678
Maddocks, 2015, Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia., JAMA Oncol, 1, 80, 10.1001/jamaoncol.2014.218
de Rooij, 2012, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia., Blood, 119, 2590, 10.1182/blood-2011-11-390989